Latest news and press releases about Vyome Holdings, Inc. (HIND): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Price
| Price | $1.96 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.32 |
| EV / EBITDA | -0.67 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -254.62% |
| Return on Invested Capital | -57.53% |
| Return on Assets | -123.23% |
| Gross Margin | 46.50% |
| Operating Margin | -3250.25% |
| Net Margin | -8716.77% |
Related companies: ARMP · CCCC · CDXS · CGEN · IMDX · IPHA · NVCT
Explore sector: Healthcare · Biotechnology
More sections of HIND: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks